Iterum TherapeuticsITRMF +18.86% Days Inventory is 4,783.78 as of Sep. 2025. The stock has 4 warning signs investors should review. Among 640 Biotechnology companies, Iterum Therapeutics ranks worse than 71.25% on this metric.
The historical rank and industry rank for Iterum Therapeutics's Days Inventory or its related term are showing as below:
ITRMF'
s Days Inventory Range Over the Past 10 Years
Min: 0 Med: 0 Max: 332.97
Current: 332.97
During the past 9 years, Iterum Therapeutics's highest Days Inventory was 332.97. The lowest was 0.00. And the median was 0.00.
ITRMF's Days Inventory is ranked worse than 71.25% of 640
companies
in the Biotechnology industry
Industry Median: 184.145
vs ITRMF: 332.97
Iterum Therapeutics's Days Inventory
increased
from Sep. 2024 (0.00) to Sep. 2025 (4,783.78).
It might indicate that Iterum Therapeutics's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Iterum Therapeutics's Inventory Turnover for the
three
months ended in Sep. 2025 was 0.02.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Iterum Therapeutics's Inventory-to-Revenue for the
three
months ended in Sep. 2025 was 2.69.
Iterum Therapeutics (OTCPK:ITRMF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Iterum Therapeutics's Inventory Turnover for the
three
months ended in Sep. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Iterum Therapeutics's Inventory to Revenue for the
three
months ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Iterum Therapeutics Days Inventory Related Terms
Iterum Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITRMF vs ENSC, PPCB, REVB: Days Inventory Comparison
For the Biotechnology subindustry, Iterum Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a Days Inventory of 4,783.78 as of Sep. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #456 out of 640 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Iterum Therapeutics' Days Inventory too high?
Iterum Therapeutics' current Days Inventory is 4,783.78. The Biotechnology industry median Days Inventory is 184.15. Iterum Therapeutics' value of 4,783.78 is 2497.8% above this industry median. Based on the distribution chart, Iterum Therapeutics ranks #456 out of 640 companies in the Biotechnology industry, which is below the industry midpoint.
How does Iterum Therapeutics' Days Inventory compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #456 out of 640 companies for Days Inventory. This places Iterum Therapeutics in the lower half of its industry. The industry median Days Inventory is 184.15. Iterum Therapeutics' value of 4,783.78 is 2497.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iterum Therapeutics's current Days Inventory of 4,783.78 is 2497.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Iterum Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current Days Inventory is 4,783.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Days Inventory of 4,783.78. The current Days Inventory is 4,783.78 and 2497.8% above the Biotechnology industry median of 184.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Days Inventory is 4,783.78 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 